Skip to main content

Table 3 Clinical characteristics and outcomes of the patients

From: A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis

Case

Age

Histology

CSF cytology response

Neurological assessment

CNS response

Extra-CNS response

PFS (m)

OS (m)

1

53

ILC

Yes

Improved

Responder

No PD

10.7

10.7

2

65

NA

NA

NA

NA

NA

0.7

0.7*

3

35

IDC

No

Improved

Non-responder

No PD

7.6

7.6

4

63

IDC

Yes

Improved

Responder

No PD

9.0

9.0

5

63

IDC

Yes

Improved

Responder

Liver PD

4.7

4.7

6

30

IDC

No

Progressed

Progression

Breast PD

2.9

2.9

7

49

IDC

NA

NA

NA

NA

0.7

0.7

8

56

IDC

NA

NA

NA

NA

1.6

1.6

  1. *Censored.
  2. Abbreviations: ILC invasive lobular carcinoma, NA not available, IDC invasive ductal carcinoma, PD progressive disease, Bev bevacizumab administration, PFS progression free survival, OS overall survival.